EMD Millipore, Merck's life-sciences unit, has expanded its EMPROVE portfolio of pharmaceutical raw materials. The expanded portfolio of pharmaceutical raw materials assists drug-product manufacturers' risk assessment workflows and supplier qualifications. Read More »

Janssen Biotech said on Monday that it has submitted a supplemental New Drug Application (sNDA) for IMBRUVICA (ibrutinib) to the U.S. Food and Drug Administration for front-line use in patients with chronic lymphocytic leukemia (CLL). Read More »

Generic-drug maker Mylan N.V. said on Monday that it has officially launched its formal offer to acquire all outstanding ordinary shares of Perrigo Co. Plc, based in Ireland. "With the overwhelming support of Mylan shareholders, today we officially are taking our offer directly to the Perrigo shareholders,” Mylan Executive Chairman Robert Coury said. Read More »

An article in the medical journal Health Affairs this month cited research on the positive impact of reducing the cost of prescription drugs and other medical costs from the NACDS/PhRMA. Read More »

Sen. Bernie Sanders (I-Vt.) and House Oversight and Government Reform Committee Ranking Member Elijah Cummings (D-Md.) recently introduced legislation to address skyrocketing increases in prescription drug prices. Read More »

Soligenix, Inc., a late-stage biopharmaceutical company, has started treatment on patients enrolled in its Phase 2 clinical trial of SGX942 for the treatment of oral mucositis in head and neck cancer patients. Read More »

TG Therapeutics, Inc. announced Wednesday the start of a Phase 1/2 clinical study investigating the use of TGR-1202, TG Therapeutic’s oral PI3K delta inhibitor and TG-1101 (ublituximab), in patients with relapsed or refractory CLL. Read More »

Zafgen, Inc. announced Wednesday the completed enrollment of ZAF-203, a Phase 2b clinical trial of beloranib in the treatment of patients with both severe obesity and type 2 diabetes. Read More »

MorphoSys AG recently provided an update on the clinical development outlook for its proprietary drug pipeline. Read More »

The CVS Health Research Institute recently conducted a study that showed that members of drug benefit plans with narrow pharmacy networks demonstrated improved medication adherence. Read More »

Pluristem Therapeutics Inc. on Wednesday announced it has completed a successful meeting with the U.S. Food and Drug Administration (FDA) about the start of a Phase I clinical trial for its PLX-R18 cells in the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation. Read More »

Gordagen Pharmaceuticals announced on Tuesday results for the first part of its Phase I clinical trial of a Single Ascending Dose Pharmacokinetics study. Read More »

Tetraphase Pharmaceuticals, Inc. announced Tuesday that the IGNITE2 phase 3 clinical trial of eravacycline administered as an IV to oral transition therapy for the treatment of complicated urinary tract infections failed to meet its primary endpoint of statistical non-inferiority compared to levofloxacin. Read More »

Tim Wentworth, the company's current president, will take the helm in May 2016. Read More »

The Association of Clinical Research Organizations is launching its second CRO Innovation Month with the theme of "Transforming Patient Centered Drug Development." Read More »

RedHill Biopharma Ltd. announced Tuesday additional supportive data from the first Phase III study with RHB-105 for eradication of H. pylori. Read More »

Immunicum AB recently signed a research agreement with Rutgers Cancer Institute of New Jersey to supply the institution with the company's adenovirus (Ad5PTDf35) technology. Read More »

Company to begin Phase IIb clinical trial of IFNa-Kinoid in Systematic Lupus Erythematosus Read More »

Villa Medical Clinic in Newburg, Oregon, recently chose Allscripts Chronic Care Management (CCM) Program to start ongoing monthly outreach to hundreds of patients who suffer from two or more chronic conditions without adding staff or increasing employee workloads. Read More »

AstraZeneca said Sept. 3 that the U.S. Food and Drug Administration has approved Brilinta (ticagrelor) tablets at a new 60 mg dose to be used in patients with a history of heart attack after the first year. Read More »